Patents by Inventor Bernard T Golding

Bernard T Golding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED QUINAZOLINES
    Publication number: 20080176875
    Abstract: This invention relates to the discovery of prodrugs of 3- or 5-substituted analogues of the selective platelet lowering agent anagrelide which have reduced potential for cardiovascular side-effects and which should therefore lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to prodrugs of certain imidazoquinazoline derivatives which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting the formation of blood platelets.
    Type: Application
    Filed: November 28, 2007
    Publication date: July 24, 2008
    Applicant: SHIRE LLC
    Inventors: Richard Franklin, Bernard T. Golding, Peter A. Cicala
  • Cyclin dependent kinase inhibitors
    Patent number: 6677345
    Abstract: A range is disclosed of pyrimidine derivatives (I) which can act as inhibitors of cyclin dependent kinases (CDK's) and which thereby can provide useful therapeutic compounds for use in treatment of tumours or other cell proliferation disorders. The compounds of this invention bind to CDK molecules in a manner that appears to differ from that of known CDK inhibitors such as olomoucine and roscovitine.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: January 13, 2004
    Assignee: Cancer Research Campaign Technology Limited
    Inventors: Roger J Griffin, Alan H Calvert, Nicola J Curtin, David R Newell, Bernard T Golding, Jane A Endicott, Martin E M Noble, Francis T Boyle, Philip J Jewsbury
  • Benzimidazole compounds
    Patent number: 6310082
    Abstract: Benzimidazole-4-carboxamide compounds (I) which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. In formula (I), R and R′ may each be selected independently from hydrogen, alkyl, hydroxyalkyl (e.g. CH2CH2OH), acyl (e.g. acetyl or benzoyl) or an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group. R is generally a substituted phenyl group in the most preferred compounds. The compounds may also be used in the form of pharmaceutically acceptable salts or pro-drugs.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: October 30, 2001
    Assignee: Newcastle University Ventures Limited
    Inventors: Roger J Griffin, Alan H Calvert, Nicola J Curtin, David R Newell, Bernard T Golding
  • Cyclin dependent kinase inhibiting purine derivatives
    Patent number: 6303618
    Abstract: Method of treating a tumour or other cell proliferation disorder which comprises administering an effective amount of a purine compound which inhibits cyclic dependent kinase activity. Novel purine compounds and pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: January 12, 2000
    Date of Patent: October 16, 2001
    Assignee: Cancer Research Campaign Technology Limited
    Inventors: Roger J Griffin, Alan H Calvert, Nicola J Curtin, David R Newell, Bernard T Golding, Jane A Endicott, Martin E M Noble, Francis T Boyle, Philip J Jewsbury
  • Pyrimidopyrimidine compounds
    Patent number: 6297250
    Abstract: A range of dipyridamole analogues useful for inhibiting transport of nucleosides or purines across cell membranes, thereby to potentiate the activity of various cytotoxic antitumor drugs, is disclosed.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: October 2, 2001
    Assignee: Newcastle University Ventures Limited
    Inventors: Roger J Griffin, Nicola J Curtin, Bernard T Golding, Alan H. Calvert, David R. Newell
  • Tetracyclic compounds for enhancing biosynthesis of erythropoietin, compositions containing same, and methods of use thereof
    Patent number: 5985913
    Abstract: The present invention provides a compound in substantially pure form having the structure: ##STR1## wherein each of R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 may independently be hydrogen, halogen, nitro, CF.sub.3, hydroxy, C.sub.1-5 alkyl, aryl or OR.sub.9, wherein R.sub.9 is C.sub.1-5 alkyl, wherein R.sub.10 is COC.sub.1-5 alkyl; or wherein any two consecutive R groups may be members of a C.sub.5 -C.sub.6 membered ring, and wherein the intracyclic-dashed line represents a covalent bond which may be present or absent, with the proviso that when R.sub.10 is present, the exocyclic-covalent bond is absent, and when R.sub.10 is absent, the exocyclic-covalent bond is present, and with the proviso that when R.sub.10 is absent, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 cannot all be hydrogen and when R.sub.10 is absent, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 cannot all be hydrogen when either R.sub.1, R.sub.2, R.sub.3, or R.sub.
    Type: Grant
    Filed: April 29, 1998
    Date of Patent: November 16, 1999
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Jonathan Gareth Williams, David R. Houck, David Edward Smith, Daniel Lee Rathbone, David Charles Billington, Bernard T. Golding, Eric W. Collington, John Kitchin, Nicholas Rich